news
Oxford Genetics licenses CRISPR technology for biotherapeutic discovery
Licensing agreement will expand Oxford Genetics growing bio-therapeutic discovery, design and development service business.
List view / Grid view
CRISPR
news
New chlamydia drug targets discovered using CRISPR and stem cells
Scientists have created an innovative technique for studying how chlamydia interacts with the human immune system...
news
New potential treatment for aggressive brain cancer in children
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
news
Premature cell differentiation leads to disorders in pancreatic development
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…
news
Charles River Laboratories announces launch of triple-immunodeficient mouse model for oncology research
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model...
webinar
Vertical integration of CRISPR/Cas9 in drug discovery
10 February 2017 | By Charles River
In this webinar, Charles River discuss the utilisation of CRISPR/Cas9 technology in drug discovery, with an emphasis on generation of in vitro models for high-throughput screening, and creating new mouse models...
news
Enhanced CRISPR allows exploration of disease in every cell type
2 December 2016 | By Niamh Louise Marriott, Digital Editor
These systems will allow researchers worldwide to rapidly and accurately explore the changing role of genes as the cells develop into tissues...
news
Charles River demonstrates CRISPR/Cas9 genome engineering expertise
2 December 2016 | By Charles Rivers Laboratories
Charles River Laboratories has launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology...
article
C is for CRISPR
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology
news
Vulnerabilities of leukaemia cells revealed using CRISPR genome editing technique
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers from the Wellcome Trust have adapted a CRISPR gene editing technique and used it to find new therapeutic targets for acute myeloid leukaemia...
webinar
Use of IntelliCyt’s iQue Screener for high-throughput screening of small molecules, CRISPRs and stem cells
29 September 2016 | By Intellicyt
This webinar highlights the use of the iQue Screener for high-throughput screening of stem cells, small molecules and CRISPR functional screening, presented by David Sykes, M.D., Ph.D., Researcher from Massachusetts General Hospital and Thibault Jonckheere, CEO and Séverine Giltaire, Senior Scientist from ImmunXperts...
news
CRISPR technology inactivates cancer mutations
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CRISPR/Cas9 is likely one of the most revolutionary tools in biotechnology, with tremendous implications for a broad range of biological and medical disciplines. As programmable scissors this technology allows cleavage of DNA at predefined sites in the genome of cells...
news
CRISPR gene editing could treat sickle cell disease
15 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Foetal haemoglobin lacks beta sub-units and has gamma sub-units instead. Thus, beta-thalassemia or SCD–associated mutations, which impair the production or function of the beta sub-unit, do not cause problems with foetal haemoglobin, which can transport oxygen effectively in adults...
news
Mkx gene revealed as crucial for keeping tendons healthy
14 July 2016 | By Victoria White, Digital Content Producer
The Scripps Research Institute scientists behind the study say their findings may bring doctors closer to using gene therapies to grow and repair tendons...
news
Regeneron and Intellia collaborate to discover CRISPR/Cas therapeutics
12 April 2016 | By Victoria White, Digital Content Producer
In addition to the discovery, development and commercialisation of new therapies, the companies will focus on technology development of the CRISPR/Cas platform...
